Slide 1: Second Quarter 2020 Financial Results & Business Update
Second Quarter 2020 Financial Results & Business Update July 29, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Introduction Sandy Coombs, VP, Investor Relations Opening Remarks Richard Pops, Chief Executive Officer Q2 2020 Financial Results; 2020 Financial Expectations Jim Frates, Chief Financial Officer Q2 2020 Commercial Review Todd Nichols, Chief Commercial Officer R&D Pipeline and Governance Update Richa
Slide 4: Focus on Three Strategic Imperatives
Focus on Three Strategic Imperatives Commercial execution Maximizing the opportunities for both ARISTADA® and VIVITROL® and preparing to leverage commercial infrastructure with the potential launch of ALKS 3831 Aggressive development of pipeline programs Focus on high-value opportunities that we bel
Slide 5: Q2 2020 Financial Results Summary
Q2 2020 Financial Results Summary In millions
Slide 6: Second Quarter 2020 Revenue Summary
Second Quarter 2020 Revenue Summary In millions, except % Q2’20 Q2’19 ∆ Q2’20 vs. Q2’19 VIVITROL® $71.6 $88.2 (19%) ARISTADA® $58.8 $48.4 21% Manufacturing & Royalty Revenue $116.5 $127.9 (9%) R&D and License Revenues $0.6 $15.3 (96%)* Total Revenue $247.5 $279.9 (12%) Amounts in the table above do
Slide 7: Financial Expectations for Year Ending Dec. 31, 2020
(in millions, except per share amounts) Financial Expectations for Year Ending Dec. 31, 2020 Revenues $965 – 1,005 COGS $180 – 190 R&D Expense $370 – 395 SG&A Expense $525 – 550 Amortization of Intangible Assets ~$40 Other Income, Net $10 – 15 Income Tax Expense $10 – 15 GAAP Net Loss $(145) – (175)
Slide 8: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations Q2 year-over-year net sales decline of 19% to $71.6M, driven by unit decline of 22% Gross-to-net deductions: 46% in Q2’20, compared to 48% in Q2’19 and 49% in Q1’20 $6.5M favorable impact of lower gross-to-nets in Q2’20 reflect lower return rate and favorable s
Slide 9: ARISTADA Performance
ARISTADA® Performance Q2 year-over-year net sales growth of 21% to $58.8M, driven by unit growth of 25% Growth reflects resilient underlying demand Gross-to-net deductions: 53% in Q2’20, compared to 48% in Q2’19 and 52% in Q1’20 Increased gross-to-nets reflect increased Medicaid utilization Inventor
Slide 10: ARISTADA: Prescription Growth Trends
ARISTADA®: Prescription Growth Trends Q2 year-over-year growth of 29% on TRx months of therapy (MOT) basis Compared to overall atypical long-acting injectable (LAI) market growth of 7% Market share: NRx: 10% of atypical LAI market prescriptions (MOT) in June 2020 Utilization of two-month dose drove
Slide 11: ALKS 4230: Advancing the Clinical Development Program
ALKS 4230: Advancing the Clinical Development Program ALKS 4230 is differentiated from other IL-2 variant programs in active clinical development Stable fusion protein molecular structure Potential for subcutaneous administration Current evaluation in the clinic as a monotherapy ARTISTRY clinical de
Slide 12: ALKS 3831 Activities
ALKS 3831 Activities Awareness through scientific exchange Presented new datasets from ENLIGHTEN pivotal program at spring virtual medical meetings Payer engagement Conducted preliminary engagement with payers that represent more than half of the potential class volume, as well as key federal and re
Slide 13: Governance and Corporate Responsibility Updates
Governance and Corporate Responsibility Updates Governance Updates Declassification of Alkermes’ Board of Directors (the Board) The Board will recommend that shareholders approve a proposal at the company’s 2021 Annual General Meeting of Shareholders to declassify the Board Currently, the Board has
Slide 14: www.alkermes.com
www.alkermes.com